Antineoplastics
1
Reactions 1429 - 24 Nov 2012 S Antineoplastics Cytopenia and febrile neutropenia: case report A 31-year-old man developed recurrent grade 3/4 cytopenias and febrile neutropenia while receiving R- Hyper-CVAD therapy with rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone [dosages, routes and frequencies not stated] following a diagnosis of primary thyroid Burkitt’s lymphoma. He had a complete response after four cycles, but his treatment protocol was changed to R-CHOP due to recurrent cytopenia and febrile neutropenia [time to reaction onset not stated]. At a 6-month follow-up, PET scans were normal. Author comment: "R-Hyper-CVAD therapy (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone) was administered . . . the protocol was changed to R-CHOP after four cycles due to recurrent grade 3/4 cytopenias and febrile neutropenia." Yildiz I, et al. Primary Burkitt’s lymphoma presenting as a rapidly growing thyroid mass. Case Reports in Oncology 5: 388-393, No. 2, May-Aug 2012. Available from: URL: http://dx.doi.org/10.1159/000341260 - Turkey 803080287 1 Reactions 24 Nov 2012 No. 1429 0114-9954/10/1429-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1429 - 24 Nov 2012
SAntineoplastics
Cytopenia and febrile neutropenia: case reportA 31-year-old man developed recurrent grade 3/4
cytopenias and febrile neutropenia while receiving R-Hyper-CVAD therapy with rituximab, cyclophosphamide,vincristine, doxorubicin and dexamethasone [dosages,routes and frequencies not stated] following a diagnosis ofprimary thyroid Burkitt’s lymphoma. He had a completeresponse after four cycles, but his treatment protocol waschanged to R-CHOP due to recurrent cytopenia and febrileneutropenia [time to reaction onset not stated]. At a6-month follow-up, PET scans were normal.
Author comment: "R-Hyper-CVAD therapy (rituximab,hyperfractionated cyclophosphamide, vincristine, doxorubicinand dexamethasone) was administered . . . the protocol waschanged to R-CHOP after four cycles due to recurrentgrade 3/4 cytopenias and febrile neutropenia."Yildiz I, et al. Primary Burkitt’s lymphoma presenting as a rapidly growing thyroidmass. Case Reports in Oncology 5: 388-393, No. 2, May-Aug 2012. Availablefrom: URL: http://dx.doi.org/10.1159/000341260 - Turkey 803080287
1
Reactions 24 Nov 2012 No. 14290114-9954/10/1429-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
